Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity. Source summary: Buy Canagliflozin to support advanced biochemical research; order now for reliable supply and unlock new possibilities in carbohydrate metabolism studies.
Products > Drug Discovery > Impurities > Anti-Diabetic > Canagliflozin and Impurities | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.